

HLS Therapeutics®

Gilbert Godin | CEO
Tim Hendrickson | CFO

Q1 2022 Results Conference Call
May 5, 2022

Forward-looking statements

Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “project”, “forecast”, “target”, “expect”, “seek”, “endeavour”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, should, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of known and unknown risks and uncertainties which would cause actual results or events to differ materially from those presently anticipated. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this presentation. These factors should be considered carefully and prospective investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this presentation are based upon what HLS currently believes to be reasonable assumptions, HLS cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, HLS does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

*** All figures in USD unless otherwise noted.**

Vascepa: strong rebound in physician interaction in March



40% decrease in average number of live calls in January/February

13% of January/February calls were in-person

March call activity reaches new monthly high

>80% of March calls were in-person

Provided May 5, 2022, as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

Impact of Omicron on large CV markets in Q1 2022



Vascepa grew Rx volumes 12% in Q1 despite Omicron headwinds

Provided May 5, 2022, as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update

Vascepa: prescription momentum growing...

Weekly script data since launch



Source: Weekly Rx, 2020 - 2022, IQVIA

...fueled by growth catalysts

Private market access
- >90% eligible for coverage

Inclusion in Canadian medical society guidelines
- Canadian Cardiovascular Society, Heart & Stroke, Thrombosis Canada

Salesforce expansion
- Pfizer agreement effective Q3 2021

COVID-19 restrictions lifting
- Easing across Canada

Public market access
- Listing agreements in coming months

Provided May 5, 2022, as part of an oral presentation and qualified by such, contains forward-looking statements, actual results may vary materially; HLS disclaims any duty to update



HLS Therapeutics®

Gilbert Godin | CEO
Tim Hendrickson | CFO

Q1 2022 Results Conference Call
May 5, 2022